Print ISSN: 2395-1443
Online ISSN: 2395-1451
CODEN : IJCEKF
Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...Original Article
Author Details :
Volume : 7, Issue : 1, Year : 2021
Article Page : 190-193
https://doi.org/10.18231/j.ijceo.2021.040
Abstract
Purpose: To evaluate the efficacy of intravitreal aflibercept in diabetic macular edema unresponsive to prior intravitreal anti VEGF and steroid therapy.
Materials and Methods: 10 eyes were prospectively investigated. Each eye was treated with intravitreal aflibercept in case of central macular edema unresponsive to prior anti VEGF therapy and intravitreal steroid. Patient were evaluated preoperatively with BCVA, OCT and fundus evaluation and IOP and followed up at 15 days, 6 weeks.
Results: Mean BCVA at presentation was 0.85 log MAR, and that improved to at 15 days and 45 days of intravitreal aflibercept, 0.65 log MAR and 0.52 log MAR. Mean central macular edema at presentation was 662.5 µm (380-905µm), after 15 days was 403µm (185-705µm) and after 45 days was 261.25µm (120-507 µm).
Conclusion: Intravitreal aflibercept can be an option to treat unresponsive diabetic central macular edema.
Keywords: VEGF, Intravitreal Aflibercept.
How to cite : Anand Babu M N, Prashanth C N, Natesh S, Diabetic macular edema shows a positive response to Aflibercept after previous unresponsive intravitreal Anti-VEGF and steroid therapy. Indian J Clin Exp Ophthalmol 2021;7(Special Issue):190-193
This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.